Dominic Stockey Appointed Executive Vice President at Pathology Ventures

Pathology Ventures, LLC (PVL), a network representing over 500 pathologists, has appointed Dominic Stockey as its executive vice president. Stockey will oversee the company's collaborations with sponsors in the pharmaceutical, diagnostic, and research sectors as PVL expands its biomarker standards and industry programs.

In his new role, Stockey will manage business operations, strategic partnerships, and enterprise development. He joins PVL from the investment banking industry, where he spent seven years and worked on more than 15 transactions across diagnostics, life sciences, and healthcare.

"Pathologists are central to getting patients the right biomarker testing, and gaps in that testing have real consequences for treatment," said Sam Caughron, MD, President of PVL. "Dominic brings the business leadership to turn that work into programs industry partners can invest in, while making sure our member practices stay independent."

Founded in 2025, PVL enables pathology practices to collaborate on biomarker programs and industry projects without relinquishing ownership. Stockey and PVL leadership are scheduled to attend the CAP26 conference in Las Vegas from October 3–6.